Drug Trial Radar · NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
539
Actual
Start
Sep 9, 2013
Primary completion
Dec 31, 2026
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Pharmacyclics LLC.
- First posted
- Mar 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Diffuse Large B-cell Lymphoma
- Waldenstrom Macroglobulinemia
- Chronic Graft Versus Host Disease
Interventions
IbrutinibDrug
Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants affected by an adverse eventTime frame: Up to 30 days after the last dose of study drug, or until the start of a subsequent systemic anti-cancer therapy, if earlier
Locations
156 sites in 29 countries. Site status is shown where the registry gives one.
Site not named
Duarte, California
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Stanford, California
Site not named
Norwalk, Connecticut
Site not named
Marietta, Georgia
Site not named
Chicago, Illinois
Site not named
Goshen, Indiana
Site not named
Westwood, Kansas
Site not named
Louisville, Kentucky
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Battle Creek, Michigan
Site not named
Detroit, Michigan
Site not named
St Louis, Missouri
Site not named
Lebanon, New Hampshire
Site not named
Hackensack, New Jersey
Site not named
New York, New York
Site not named
Goldsboro, North Carolina
Site not named
Columbus, Ohio
Site not named
Eugene, Oregon
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Sioux Falls, South Dakota
Site not named
Houston, Texas
Site not named
Charlottesville, Virginia
Site not named
Seattle, Washington
Site not named
Morgantown, West Virginia
Site not named
Madison, Wisconsin
Site not named
Ciudad Autonoma Buenos Aires, Argentina
Site not named
Ciudad de Buenos Aires, Argentina
Site not named
Adelaide, Australia
Site not named
Coburg, Australia
Site not named
Concord, Australia
Site not named
Heidelberg, Australia
Site not named
Melbourne, Australia
Site not named
Perth, Australia
Site not named
Prahran, Australia
Site not named
Wahroonga, Australia
Showing 40 of 156 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.